Literature DB >> 3570557

Differential expression of endogenous sugar-binding proteins (lectins) in murine tumor model systems with metastatic capacity.

H J Gabius, G Bandlow, V Schirrmacher, G A Nagel, K Vehmeyer.   

Abstract

In order to investigate possible differences in sugar binding activities of strongly versus weakly metastatic tumors, sugar-binding molecules (endogenous lectins) of murine tumor cells differing in metastatic capacity were analyzed by affinity chromatography on supports with immobilized sugars or glycoproteins and compared. After elution with specific sugar in the absence of Ca2+-ions, the proteins were separated by sodium dodecyl sulfate-polyacrylamide slab gel electrophoresis. In comparison to a weakly metastatic subline (Eb) spontaneous strongly metastatic variants (ESb) of a murine lymphoma contained additional sugar receptors for N-acetylglucosamine (Mr 30 kDa) and maltose (Mr 64 kDa, 62 kDa, 54 kDa and 32 kDa), and lacked one sugar receptor for myoinositol (Mr 85 kDa), N-acetylglucosamine (Mr 23 kDa) and maltose (Mr 22 kDa), respectively. The strongly metastatic variant ESb expressed the common beta-galactoside-specific lectin to a higher extent and receptors for myo-inositol, melibiose and mannan to a lower extent. In another model system derived from the murine mastocytoma cell line P 815 X 2A, biochemical analysis of the liver-metastasizing variant P 815 X 2B revealed additional characteristic N-acetylgalactosamine- and maltose-specific binding proteins. This variant had reduced amounts of receptors for beta-galactosides and fucose in comparison to the parental clone. In a third tumor system a similar qualitative difference was disclosed: a metastatic variant derived from spleen metastases displayed a sugar receptor profile with 5 additional beta-galactoside-binding proteins when compared to its parental clone 6-6#3 + F, which is a virally transformed fibroblast line. The results show that metastatic variants of 3 murine tumor models consisting of lymphomas, mastocytomas and sarcomas are characterized by qualitative and quantitative alterations in the profiles of sugar-binding proteins.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3570557     DOI: 10.1002/ijc.2910390517

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Malignant and normally developing trophoblastic cells of human placenta display different characteristics defined by histochemical and biochemical mapping of endogenous lectins.

Authors:  H J Gabius; P L Debbage; N Lang; W Lange
Journal:  Histochemistry       Date:  1989

2.  Inhibition of liver tumor cell colonization in two animal tumor models by lectin blocking with D-galactose or arabinogalactan.

Authors:  J Beuth; H L Ko; V Schirrmacher; G Uhlenbruck; G Pulverer
Journal:  Clin Exp Metastasis       Date:  1988 Mar-Apr       Impact factor: 5.150

Review 3.  Clinical application of various plant and endogenous lectins to leukemia.

Authors:  H J Gabius; K Vehmeyer; S Gabius; G A Nagel
Journal:  Blut       Date:  1988-04

4.  Endogenous sugar receptor pattern in human glioblastomas and gangliocytomas studied by histochemical application of biotinylated (neo)glycoproteins and affinity chromatography.

Authors:  H J Gabius; K P Hellmann; T Dimitri; A Bardosi
Journal:  Histochemistry       Date:  1989

5.  Lineage- and differentiation-dependent alterations in the expression of receptors for glycoconjugates (lectins) in different human hematopoietic cell lines and low grade lymphomas.

Authors:  S Gabius; K P Hellmann; T Ciesiolka; G A Nagel; H J Gabius
Journal:  Blut       Date:  1989-08

6.  Membrane N-acetylglucosamine: expression by cells in rheumatoid synovial fluid, and by pre-cultured monocytes.

Authors:  M Sharif; L S Wilkinson; J Edwards; G A Rook
Journal:  Br J Exp Pathol       Date:  1989-10

7.  Murine tumor cells metastasizing selectively in the liver: ability to produce hepatocyte-activating cytokines interleukin-1 and/or -6.

Authors:  K Takeda; N Fujii; Y Nitta; H Sakihara; K Nakayama; H Rikiishi; K Kumagai
Journal:  Jpn J Cancer Res       Date:  1991-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.